AzTrials
AzTrials

Renal ColicPhase 4NCT00451061

The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones

A Phase 4 study testing Alfuzosin and Tamsulosin in people with Renal Colic, run by Soroka University Medical Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Most of the patients suffering from renal colic have a distal ureterolithiasis. It had been demonstrated that α adrenoreceptors antagonists, given to patients suffering from renal colic, due to distal ureterolithiasis, had increased the frequency of stone expulsion rate , reduced the time to expulsion and reduced… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Renal Colic
What is being tested?
Alfuzosin and Tamsulosin
How many people
120 participants
Where
1 siteIsrael
Study dates
Apr 2007to not given
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • renal colic due to radiologically proven distal ureteral stones

Who cannot join

  • stone larger than 10 mm
  • fever
  • urinary tract infection
  • additional stones, that might be the reason for the renal colic
  • severe hydronephrosis
  • known sensitivity to α blockers
Show all 14Show fewer
  • concomitant treatment with α blockers, β blockers, calcium antagonists, and nitrates
  • pregnancy
  • inability to provide informed consent
  • a history of surgery or endoscopic procedures in the urinary tract
  • history of spontaneous stone expulsion
  • known ureteral stricture
  • diabetes
  • blood pressure values lower than 100/70 mm hg

Trial locations and contacts

1 site in 1 country.

Eran Rosenberg, M.D contact

972-8-6400626

eranro@clalit.org.il

Israel1 site
  • Urology department, Soroka university medical center

    Beer-Sheva, P,o,box 151, 84101

Other trials in Israel

About this study

Most of the patients suffering from renal colic have a distal ureterolithiasis. It had been demonstrated that α adrenoreceptors antagonists, given to patients suffering from renal colic, due to distal ureterolithiasis, had increased the frequency of stone expulsion rate , reduced the time to expulsion and reduced analgesics consumption.Most of the studies evaluated the efficacy of Tamsulosin, which is a selective α 1A and α 1D adrenoreceptors antagonist.(The lower intramural portion of the ureter, where it passes through the detrusor muscle contains mostly α 1D and α 1A adrenergic receptors)

Only one study these days describes the use of Alfuzosin, which is an α adrenergic receptor blocker and not selective for any α 1 adrenergic receptor, for expulsion of distal ureteric stones.Alfuzosin is a drug with a proven efficacy and considered uroselective with high specificity and sensitivity, for the treatment of BPH. There was no significant difference in efficacy between the two α blockers (Alfuzosin vs. Tamsulosin) concerning symptoms relief or flow improvement.

The objective of this study is to compare patient who would receive the standard treatment for distal ureterolithiasis (analgesics, Rowatinex) to patients who would receive also a non selective α blocker (Alfuzosin) or a selective α blocker (Tamsulosin). This in order to evaluate the efficacy of treatment with α blockers for expulsion of distal ureterolithiasis.

Read the detailed description

The efficacy of alpha-blockers for expulsion of distal ureteral stones

Urolithiasis is estimated among 8%-15% of the population in Europe and North America.1-5 Patient who suffer from renal colic represent a very common reason for visiting the emergency room or for hospitalization. The stones are usually located in the ureter, mostly in its lower third.

Some of the distal ureteral stone would pass spontaneously, depending on a few factors such as the stone's size, location, shape, smooth muscle spasm, submucosal edema and anatomy.

Since renal colic is one of the most painful conditions, the time until expulsion of the stone should be reduced as much as possible. In case the stone obstructs and does'nt pass, damage to the kidney might occur, and surgical intervention should be considered. However, surgery and anesthesia are not risk free.

The local reaction to obstructing ureterolithiasis manifests in ureteric smooth muscle contraction, edema, inflammation and pain. The ureter contains α -adrenergic receptors in the smooth muscle layer, along it's entire length. Since these receptors play an important role in ureteric contraction during renal colic, several studies were performed in order to evaluate the effect of α receptors blockade. These studies had demonstrated that different α blockers had increased the frequency of stone expulsion rate among patients with renal colic, reduced the time to expulsion and reduced analgesics consumption.

Most of the studies evaluated the efficacy of Tamsulosin, which is a selective α 1A and α 1D adrenoreceptors antagonist. The lower intramural portion of the ureter, where it passes through the detrusor muscle contains mostly α 1D and α 1A adrenergic receptors.

A common treatment these days to obstructive uropathy due to benign prostatic hypertrophy (BPH) is Alfuzosin. Despite the fact that it is an α adrenergic receptor blocker and not selective for any α 1 adrenergic receptor subtypes, it is a drug with a proven efficacy and considered uroselective with high specificity and sensitivity, for the treatment of BPH. There was no significant difference in efficacy between the two α blockers (Alfuzosin vs. Tamsulosin) concerning symptoms relief or flow improvement, and side effects were similar.

Only one study these days describes the use of Alfuzosin for expulsion of distal ureteric stones.

The objective of this study is to compare patient who would receive the standard treatment for distal ureterolithiasis (analgesics, Rowatinex) to patients who would receive also a non selective α blocker (Alfuzosin) or a selective α blocker (Tamsulosin). This in order to evaluate the efficacy of treatment with α blockers for expulsion of distal ureterolithiasis.

Materials and methods:

Participants - Individuals who will be referred to the emergency room or be admitted to the urology department in Soroka hospital, (Beer-Sheva, Israel) because of acute renal colic. The patient would be considered for the study only if the stone would be located in the distal ureter.

This study is estimated to include 120 patients and last 6 months. The patients would be divided randomly to three groups:

  1. Patients with renal colic that would receive Abitren and Rowatinex B. Same therapy plus Tamsulosin (0.4 mg/daily) C. Same therapy as A plus Alfuzosin (10 mg/daily)

The treatment would last up to 4 weeks.

The duration of the trial would be until expulsion of the stone, but not longer than 4 weeks. Patients who would not pass the stone spontaneously, would be referred to intervention (ESWL, ureteric stent insertion, ureteroscopy)

Treatment discontinuation would be due to hospitalization (intractable pain, fever, the need for an intervention)

The α blockers treatment would be once daily, until stone expulsion, or up to four weeks.

The initial treatment protocol would be the standard treatment - I.V fluids and analgesics

Each patient would be initially evaluated by:

  • physical examination
  • abdominal radiography
  • serum creatinine and leukocytes measurement
  • urinalysis
  • renal ultrasonography
  • blood pressure measurement

The follow up:

The blood pressure measurements would be taken by the family physician, two days and one week after the beginning of the treatment. Four weeks after the treatment begins, each patient would be checked in the out patient clinic. Unenhanced CT scan, serum creatinine and blood pressure measurement would be taken. In case the patient would not pass the stone, intervention would be scheduled.

Conditions
Renal Colic
Being tested
Alfuzosin, Tamsulosin
Keywords
distal ureterolithiasis, α adrenoreceptors antagonist
Medical subject headings
Renal Colic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AlfuzosinDrug

  • TamsulosinDrug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. frequency of stone expulsion

  2. time to stone expulsion

  3. analgesics consumption

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Mar 2007 (estimated)
  2. Study startApr 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00451061
Sponsor's protocol ID
sor449907ctil
Status last verified
Feb 2007
First submitted
21 Mar 2007
Last updated
12 Jul 2012
Results posted
No
Data monitoring committee
No

Publications

  • De Sio M, Autorino R, Di Lorenzo G, Damiano R, Giordano D, Cosentino L, Pane U, Di Giacomo F, Mordente S, D'Armiento M. Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. J Endourol. 2006 Jan;20(1):12-6. doi: 10.1089/end.2006.20.12.

    PubMed 16426124
  • Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol. 2005 Jul;174(1):167-72. doi: 10.1097/01.ju.0000161600.54732.86.

    PubMed 15947613
  • Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol. 2005 Jun;173(6):2010-2. doi: 10.1097/01.ju.0000158453.60029.0a.

    PubMed 15879806
  • Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003 Dec;170(6 Pt 1):2202-5. doi: 10.1097/01.ju.0000096050.22281.a7.

    PubMed 14634379
  • Autorino R, De Sio M, Damiano R, Di Lorenzo G, Perdona S, Russo A, Quarto G, Cosentino L, D'Armiento M. The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand? Urol Res. 2005 Dec;33(6):460-4. doi: 10.1007/s00240-005-0508-0. Epub 2005 Nov 29.

    PubMed 16317534
  • Pricop C, Novac C, Negru D, Ilie C, Pricop A, Tanase V. [Can selective alpha-blockers help the spontaneous passage of the stones located in the uretero-bladder junction?]. Rev Med Chir Soc Med Nat Iasi. 2004 Jan-Mar;108(1):128-33. Romanian.

    PubMed 15688769
  • Saita A, Bonaccorsi A, Marchese F, Condorelli SV, Motta M. Our experience with nifedipine and prednisolone as expulsive therapy for ureteral stones. Urol Int. 2004;72 Suppl 1:43-5. doi: 10.1159/000076591.

    PubMed 15133333
  • Micali S, Grande M, Sighinolfi MC, De Carne C, De Stefani S, Bianchi G. Medical therapy of urolithiasis. J Endourol. 2006 Nov;20(11):841-7. doi: 10.1089/end.2006.20.841.

    PubMed 17144848
  • Porpiglia F, Vaccino D, Billia M, Renard J, Cracco C, Ghignone G, Scoffone C, Terrone C, Scarpa RM. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? Eur Urol. 2006 Aug;50(2):339-44. doi: 10.1016/j.eururo.2006.02.023. Epub 2006 Mar 3.

    PubMed 16574310
  • Beach MA, Mauro LS. Pharmacologic expulsive treatment of ureteral calculi. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1361-8. doi: 10.1345/aph.1G586. Epub 2006 Jul 18.

    PubMed 16849614
  • Lipkin M, Shah O. The use of alpha-blockers for the treatment of nephrolithiasis. Rev Urol. 2006;8 Suppl 4(Suppl 4):S35-42.

    PubMed 17216000
  • Porena M, Guiggi P, Balestra A, Micheli C. Pain killers and antibacterial therapy for kidney colic and stones. Urol Int. 2004;72 Suppl 1:34-9. doi: 10.1159/000076589.

    PubMed 15133331

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Alfuzosin and Tamsulosin in people with Renal Colic, run by Soroka University Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Eran Rosenberg, M.D (972-8-6400626, eranro@clalit.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

frequency of stone expulsion. The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00451061, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in